Tags : Patient


Thermo Fisher Expands its Direct-to-Patient Service Offerings

Shots: The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates The company’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched in early 2020 to ensure that clinical trial patients have uninterrupted access to […]Read More


Eli Lilly Reports Dosing of its First Patient with Tirzepatide

Shots: The P-III SURPASS-CVOT study involves assessing non-inferiority and superiority of tirzepatide vs Trulicity (dulaglutide, 15mg) in 12,500 patients with T2D and atherosclerotic cardiovascular disease from 30 countries. The company expects for the completion of trial in four years The 1EPs will measure time to first occurrence of MACE-3, the composite endpoint of CV death, […]Read More


Clover Reports First Patient Dosing in P-III Trial with SCB-808

Shots: The P-III study involves assessing of SCB-808 (SC) vs Enbrel (SC) in patients with ankylosing spondylitis (radiographic axial spondyloarthritis) to evaluate its safety, efficacy and PK The company utilizes its Trimer-Tag technology platform to develop novel therapies targeting trimerization-dependent pathways and is also leveraging its cGMP biomanufacturing capabilities to develop biosimilars SCB-808 is mAb […]Read More


Innovate Initiates its Dosing For P-III CeD LA 3001 Trial

Shots: The P-III study involves assessing of larazotide acetate as an adjuvant therapy vs PBO in patients with celiac disease who still experience symptoms despite being on a gluten-free diet Innovate marks to be the first company in patient dosing in P-III celiac disease. Larazotide has met 1EPs in P-IIb efficacy clinical trial enrolling 342 […]Read More


CorMedix Reports Results of Neutrolin in P-III LOCK-IT-100 Study for

Shots: The P-III LOCK-IT-100 Study involves assessing of Neutrolin vs heparin as a catheter lock solution in hemodialysis patients Th study resulted in reducing the risk of occurrence of catheter-related blood stream infections (CRBSI) by 72%, with safe and efficate results Neutrolin is non-antibiotic, antimicrobiaTYUIOl drug indicated for the prevention of bloodstream infections with the […]Read More